# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mary McLeod Bethune (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML043-SYN-TD
- Date: 1948-03-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Viola Harrington-Mbeki, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- Her breathing wakes her at night and stops her climbing stairs, and she has had to travel less **S**
- She has been told for years that it is asthma, or her weight, or her heart, and wants to know for certain which it is **S**
- She wants to keep going to Washington for the council's meetings **S**

## Your goals

- A confirmed diagnosis within three weeks: spirometry with bronchodilator response, FeNO and an echocardiogram, with the pulmonology consultation. Target: 1948-03-23. Recorded outcome: Asthma confirmed by a 21 percent, 270 mL bronchodilator response and FeNO 46 ppb; heart failure excluded; hypertensive heart disease found, two weeks after the first visit. **S**
- Asthma Control Test 20 or more, no night waking, and travel to Washington without breathlessness. Target: 1948-07-27. Recorded outcome: Asthma Control Test 22; no night waking; travelled to two board meetings. **S**
- Correct inhaler technique with her own inhaler at every visit, and a written asthma action plan she can use. Target: 1948-05-04. Recorded outcome: Technique corrected with a spacer at six weeks; action plan written at diagnosis and used during the exacerbation. **S**
- Blood pressure below 130/80 at home and in clinic. Target: 1948-07-27. Recorded outcome: Clinic 128/78; home average 126/76 on amlodipine. **S**
- No exacerbation needing oral corticosteroids. Target: 1948-07-27. Recorded outcome: Not achieved: one moderate exacerbation with a cold, treated with five days of prednisone without admission. **S**

## What we agreed to do

- Pulmonology consultation in two weeks with spirometry before and after bronchodilator, DLCO and FeNO, to confirm or refute asthma, separate it from COPD and heart disease, and plan treatment. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and hypertension monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020) **S**
- Work-up of wheeze and breathlessness: chest X-ray, ECG, blood count with eosinophils, BNP, TSH and kidney function today; transthoracic echocardiogram before the consultation; albuterol continued as needed until testing, holding it for six hours before spirometry. Guideline: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. J Am Coll Cardiol 2022;79(17):1757-1780 (PMID 35379504) (2022) **S**
- Home blood pressure readings twice daily for a week, with a validated upper-arm cuff, because clinic readings are raised. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and hypertension monographs (2026); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025) **S**
- Equity safeguards: spirometry read with race-neutral GLI Global equations, plain explanation of every result, and a check at each visit that her symptoms are not put down to her weight or age. Guideline: Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023); Pate CA, et al. Asthma Surveillance - United States, 2006-2018. MMWR Surveill Summ 2021;70(5):1-32 (PMID 34529643) (2021) **S**
- GINA track 1: budesonide-formoterol 160/4.5 mcg as maintenance and reliever (one inhalation twice daily and one as needed, no more than 12 a day), albuterol stopped; inhaler technique, adherence and Asthma Control Test at every visit; a written asthma action plan with peak flow zones; review six weeks after any change and within a week of any exacerbation. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and hypertension monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020) **S**
- Hypertensive heart disease without heart failure: amlodipine 5 mg daily (a beta-blocker avoided because of asthma), a lower-salt diet, home readings, and kidney function and potassium at follow-up. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and hypertension monographs (2026); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025) **S**
- Cardiovascular prevention: atorvastatin 20 mg daily for a 10-year ASCVD risk above 20 percent. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025) **S**
- Upper airway and reflux: fluticasone nasal spray and saline rinses, ear, nose and throat review with nasal endoscopy; omeprazole for eight weeks for heartburn with meal timing and head-of-bed elevation, then stop if settled. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and hypertension monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025) **S**
- Weight and fitness, as she chooses: a dietitian visit, a walking plan she can follow on campus and in Washington, and a later discussion of medicines for weight if she wants one. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and hypertension monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025) **S**
- Biologic assessment: not indicated while asthma is controlled on low-to-medium dose ICS-formoterol with good technique; repeat blood eosinophils and refer for biologic therapy if asthma becomes uncontrolled on step 4 to 5 treatment or there are two or more exacerbations needing oral corticosteroids in a year. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and hypertension monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025) **S**

## Follow-up

- 1948-03-09: New patient visit for four months of wheeze, night cough and breathlessness on exertion in a 72-year-old woman with long-standing asthma that was never confirmed: examination, chest X-ray, ECG, blood tests and BNP, and planning of lung function testing and an echocardiogram **S**
- 1948-03-23: Diagnosis visit: spirometry, FeNO and echocardiogram results with the pulmonology consultation; asthma confirmed, heart failure excluded, hypertensive heart disease found; start of budesonide-formoterol as maintenance and reliever **S**
- 1948-05-04: Six-week asthma review: control, inhaler technique and adherence, the ear, nose and throat result, blood pressure and reflux **S**
- 1948-07-27: Review six weeks after an exacerbation: control, repeat spirometry and FeNO, biologic assessment, blood pressure and the post-exacerbation plan **S**
- 1948-09-21: Subsequent annual wellness visit **S**

This teaching document does not replace care from a qualified clinician.
